Details of the Drug Combination

General Information of Drug Combination (ID: DC7YALS)

Drug Combination Name
Vinflunine Terameprocol
Indication
Disease Entry Status REF
Colon carcinoma Investigative [1]
Component Drugs Vinflunine   DMTJAEP Terameprocol   DMC3P45
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: KM12
Zero Interaction Potency (ZIP) Score: 2.73
Bliss Independence Score: 5.92
Loewe Additivity Score: 5.09
LHighest Single Agent (HSA) Score: 2.43

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Vinflunine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [2]
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [3]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [3]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Colon adenocarcinoma DC0KM44 COLO 205 Investigative [1]
High grade ovarian serous adenocarcinoma DCMFIL2 OVCAR-5 Investigative [4]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.